Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
about
A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Systems serology for evaluation of HIV vaccine trials.Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and SubclassesRelationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 AcquisitionTRIM5α Resistance Escape Mutations in the Capsid Are Transferable between Simian Immunodeficiency Virus Strains.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent MannerPlasticity and Epitope Exposure of the HIV-1 Envelope Trimer.Use of broadly neutralizing antibodies for HIV-1 prevention.Complex immune correlates of protection in HIV-1 vaccine efficacy trials.Adjuvants: tailoring humoral immune responses.Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by α4β7 integrin.Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.RETRACTED: A DNA inducing VLP vaccine designed for HIV and tested in miceSystems serology: profiling vaccine induced humoral immunity against HIV.A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization.Innate Lymphoid Cells in HIV/SIV Infections.HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission.Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV.Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.Advances in HIV-1 Vaccine Development.T Cell Subsets in the Germinal Center: Lessons from the Macaque Model.High-resolution definition of humoral immune response correlates of effective immunity against HIV.Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesHIV vaccine candidate activation of hypoxia and the inflammasome in CD14 monocytes is associated with a decreased risk of SIV acquisitionHarnessing T Follicular Helper Cell Responses for HIV Vaccine DevelopmentOvercoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primatesSelect gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7
P2860
Q30234577-11EB1554-9707-48B7-A3A0-5FAB9273D527Q30238729-4314E5A7-98F7-4228-8296-FAEAC5E73A38Q32183405-C4B6E45F-0F55-4D62-868D-F6AB705E1F95Q34540352-84A36583-338B-4138-85B1-02A35B0E8C61Q36118373-D158680D-E870-4DB1-93F2-17CCE53DCB4EQ37252938-7492D7D0-81C1-4B73-8D1A-2369C38640AAQ37261545-311A3CFF-4FE8-4B8A-AD66-B10072F65C32Q37448315-7E201C88-D733-4E1F-861E-A77BBCBE7D48Q37677278-68D78513-5067-4DCF-BE51-D75C708FC790Q38719420-A89FD96B-2D24-4ECF-BF1E-E151849B7946Q38725480-8B6A3416-3CC4-4B97-A6F5-4530F105EFFBQ38764543-964E470E-499C-4D2A-8B50-AA03396C4AC5Q39108779-7D782E9C-4E42-4ABE-B86D-808077633809Q39160011-CB32573B-6051-4C41-A2C8-73965F0B86F5Q39450802-A62AD8F0-F7A6-460F-80B8-DC734C839B8CQ40077472-8048C40C-7E12-4079-9608-B12A47924F4EQ40113278-EC6F9C64-8FA1-40E6-886E-C89775B24CC0Q40174150-51D3A1F0-A3FC-421F-B0F2-7E6F560175EFQ40180898-DD5397AF-8645-4CE3-A5E3-F4A05144E7AAQ40332276-BED1FEF1-95CC-4CEC-BF3F-8A4BFB837E5DQ40507703-EA885C7B-4384-4C32-9AF0-888FD03A8225Q41512554-46CBEF18-F076-4705-8EAB-05D89B4FBAAFQ47104983-634AF517-1235-4772-9AC8-3D62A91FCE54Q47296227-6CB3689D-AF5A-4F56-987E-9539A7223B25Q47364595-47EFA5CE-B594-4E45-A5BC-81E1B6FDDD69Q47554808-EE956F4A-E019-4B34-8C84-4D3E611446C1Q47616308-F9DBC11A-55A8-4323-A93E-56336BED3E6DQ50114397-ADA65527-F9F6-4045-AD69-79CD511985A8Q50209602-A7528E3D-A8FF-4225-8536-FCA85948CD0FQ51743315-E13698DB-6211-4A13-963E-76D271E70A6EQ52609661-290586D8-DE48-44E6-9352-BB874E79E9FEQ52657148-9818FFCF-D99C-400E-9569-B5FCF8DFA62DQ55022148-8288B1E8-5A21-4296-8414-33ED9CBF0A06Q55411829-038D9395-3E73-46C0-B8B7-1885956560F8Q55447637-6E0792FE-A7C6-4AFA-A782-5D44CB8B4FE4Q56517308-C2111CC1-837A-4884-97B2-0660FF1D2BA2Q56523156-D7159A29-A237-479C-9189-2BC79AE7F9C5Q56950294-CE417926-CDD2-4426-8F36-38CBF0B93401Q57299517-148012E0-CDAF-48CC-A52A-5FB4507BE896Q57751823-2A10D902-24A1-424F-B2E3-223AAB7D88C1
P2860
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@en
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@nl
type
label
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@en
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@nl
prefLabel
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@en
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@nl
P2093
P2860
P50
P356
P1433
P1476
Adjuvant-dependent innate and ...... risk of SIVmac251 acquisition.
@en
P2093
Adrian McDermott
Chris Bailey-Kellogg
Christopher J Miller
David S Quinn
David Venzon
DeVon Thompson
Diego A Vargas-Inchaustegui
Donald M Stablein
Donald N Forthal
Eric P Brown
P2860
P2888
P304
P356
10.1038/NM.4105
P407
P50
P577
2016-05-30T00:00:00Z